Cancer has long been one of the most feared diseases in the world.
Now, a groundbreaking development in vaccine technology could change the way we fight it.
In a collaboration between the University of Oxford and the pharmaceutical company GSK, researchers are working on a vaccine designed to prevent cancer in its earliest stages.
With a £50 million investment and leadership from some of the world’s top scientists, including Professor Sarah Blagden from the University of Oxford, the ambitions are high.
The goal is to detect and eliminate cancer cells before they develop into full-blown cancer.
The Vaccine
Cancer is usually diagnosed only after it has established itself in the body and caused significant damage.
According to Sarah Blagden, it can take 20 years or more for a normal cell to transform into a cancer cell.
During this long transition, however, cells undergo small changes that modern technology can now identify.
How Does the Vaccine Work?
This pre-cancer vaccine differs from traditional cancer treatments by focusing on prevention rather than treatment.
While conventional vaccines like the HPV vaccine protect against viruses that can lead to cancer, this vaccine is designed to target the body’s own cells before they become dangerous.
By identifying the unique characteristics of pre-cancerous cells, scientists can develop a vaccine that teaches the immune system to attack these cells before they reach a harmful stage.
Sarah Blagden explains that this approach gives the immune system a head start in the fight against cancer, preventing the disease from developing in the first place.
This article is based on information from Express.co.uk.
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.